Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
PENTOBARBITAL SODIUM
WDT - Wirtschaftsgenossenschaft deutscher Tierarzte eG
QN51AA01
PENTOBARBITAL SODIUM
300 Mg/Ml
Solution for Injection
VPO-Vet.Practitioner Only
Avian, Bovine, Canine, Equine Non Food, Feline, Fowl - Chicken, Guinea Pigs, Hamsters, Mink, Non Food Animals, Porcine, Rabbits,
Pentobarbital
Neurological Preparations
Authorised
2008-10-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Release 300 mg/ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance: pentobarbital sodium 300 mg Excipients: patent blue V (E 131) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection A clear, blue solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses, ponies, cattle, swine, dogs, cats, minks, polecats, hares, rabbits, guinea pigs, hamsters, rats, mice, chicken, pigeons, birds, snakes, tortoises, lizards, frogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For euthanasia in animals. 4.3 CONTRAINDICATIONS Do not use in animals intended for human or animal consumption. Do not use for anaesthetic purposes. Do not use for intracoelmic injection in chelonia as the time to death may be unnecessarily prolonged compared with intravenous administration. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 24/10/2016_ _CRN 7023396_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Carcases of animals euthanised with this product should be disposed of in accordance with national legislation. Carcases of animals euthanised with this product should not be fed to other animals due to the risk of secondary intoxication. The intraperitoneal route of administration may cause a prolonged onset of action with an increased risk of adverse effects noted in 4.6. Prior sedation is advisable. The intrapulmonary route of administration may cause a prolonged onset of action with an increased risk of adverse effects noted in 4.6 and should be reserved for cases where other routes of administration are not possible. Prior s Belgenin tamamını okuyun